NBTY Agrees To $2.1M Settlement With FTC For False DHA Claims
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission's ongoing crackdown on "bogus" health claims leads to a $2.1 million settlement with NBTY and two subsidiaries to resolve charges they overstated the amount and benefit of DHA in children's multivitamins.
You may also be interested in...
Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane
Steven Cahillane, who left his post as president of Coca-Cola Co.’s Americas division in 2013, is moving to NBTY to replace Jeffrey Nagel after the supplement manufacturer and retailer reported flat sales for its most recent earnings period and after net income dropped nearly 12% during the firm’s previous fiscal year.
Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane
Steven Cahillane, who left his post as president of Coca-Cola Co.’s Americas division in 2013, is moving to NBTY to replace Jeffrey Nagel after the supplement manufacturer and retailer reported flat sales for its most recent earnings period and after net income dropped nearly 12% during the firm’s previous fiscal year.
In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.